Document:

Amendment of Securities Purchase Agreement and Series B Unit Purchase Warrant

 Exhibit 10.1 
 AMENDMENT OF SECURITIES PURCHASE AGREEMENT AND 
 SERIES B UNIT PURCHASE WARRANT 
 The Securities Purchase Agreement dated April 29, 2008 between Cell Therapeutics, Inc. (the “Company”) and BAM Opportunity Fund LP (the
“Holder”) and the Series B Unit Purchase Warrant dated April 30, 2008 are hereby amended as follows, as of June 10, 2008. 
 WHEREAS, Section 1.1 of such Securities Purchase Agreement provides in relevant part: 
 “Series B
Convertible Notes” means the 12.50% Series B Convertible Notes of the Company to be issued under a Trust Indenture between the Company and US Bank National Association as Trustee, and of like tenor as the Convertible Notes except for the
different issuance date, the absence of an optional redemption right, a 3-year term, a 12.50% annual interest rate, and a make-whole provision based on the 3-year term and the 12.50% annual interest rate. 
 WHEREAS, Section 7 of such Series B Unit Purchase Warrant provides: 
 Termination if Partial Exercise. If the Holder makes any partial exercise of this Warrant (other than as required by
Section 2.4 of the Purchase Agreement), then Holder (or any transferee of this Warrant) shall not be allowed to ever exercise this Warrant again (except upon a Put). 
 WHEREAS, Section 2.4 of the Securities Purchase Agreement authorizes the Company to require Holder to exercise the Series B Unit Purchase Warrant to the extent of $8,000,000, and the Company has given notice of
exercise of such right. 
 WHEREAS, Holder is not now obligated to exercise any further amount of the Series B Unit Purchase Warrant, but is
willing to exercise an additional $15,000,000 of the Series B Unit Purchase Warrant forthwith if and only if the amendments provided for herein are effected. 
 WHEREAS, the Company wishes to induce such further $15,000,000 exercise of the Series B Unit Purchase Warrant by Holder. 
 NOW, THEREFORE, in consideration of the foregoing, the parties agree as follows: 
 1. Notwithstanding
anything in the Securities Purchase Agreement and the Series B Unit Purchase Warrants to the contrary, the Securities Purchase Agreement and the Series B Unit Purchase Warrants are amended to provide that all references therein to Series B
Convertible Notes or 12.50% Series B Convertible Notes shall, instead of the meaning quoted in the Recitals above, the following meaning: 
 “15% Series B Convertible Notes of the Company to be issued under a Trust Indenture between the Company and US Bank National Association as Trustee, and of like tenor as the Convertible Notes except for the
different issuance date, the absence of an optional redemption right, a 3-year term, a 15% annual interest rate, and a make-whole provision based on the 3-year term and the 15% annual interest rate.” 

 2. Effective immediately upon exercise of the Series B Unit Purchase Warrant to the cumulative total
extent of at least $23,000,000, Section 7 of the Series B Unit Purchase Warrant shall be amended to provide in full as follows: 
 “Effect of Partial Exercise. If the Holder makes any two partial exercises of this Warrant (after and not including the first $23,000,000 of exercises, which $23,000,000 includes any amount exercised as required by
Section 2.4 of the Purchase Agreement), then Holder (or any transferee of this Warrant) shall not be allowed to ever exercise this Warrant again (except upon a Put).” 
 3. The Holder agrees to exercise the Series B Unit Purchase Warrant to the cumulative total extent of at least $23,000,000 (including the amount required
by Section 2.4 of the Securities Purchase Agreement ) by no later than June 12, 2008. 
 4. The Holder agrees not to purport to
exercise or convert, before the Company increases its authorized shares of common stock, any of the derivative securities which it obtains upon the exercise the Series B Unit Purchase Warrant as contemplated by Section 3 of this Amendment.

 5. The Company shall repay when due on June 15, 2008 (and shall not extend the maturity date of) all of the Company’s
outstanding 5.75% convertible subordinated notes due June 15, 2008 and 5.75% convertible senior subordinated notes due June 15, 2008. 
 6. Except as expressly set forth in this Amendment, the Securities Purchase Agreement and the Series B Unit Purchase Warrant remain unchanged and in full force and effect. 
  

			
	CELL THERAPEUTICS, INC.
		
	By:	 	/s/ James Bianco
	
	BAM OPPORTUNITY FUND LP
		
	By:	 	/s/ Seth Morris

  

 2Letter Agreement

 Exhibit 10.1 
  

			
	June 12, 2008	 	Revised

 Mr. Stephen W. Webster 
 Dear Mr. Webster: 
 On behalf of Adolor Corporation (the “Company”), we would like to offer you the position
of Senior Vice President, Finance & Chief Financial Officer reporting directly to Michael Dougherty, President & CEO. This offer is contingent upon our receipt of employment and education references that meet our standards of
acceptability as well as: 
  

	a)	The completion of a satisfactory credit and criminal background check (in compliance with the Fair Credit Reporting Act). 

  

	b)	The completion of a successful pre-employment drug screening. The drug test must be completed within 5 days of the employment letter date. Please visit www.questdiagnostics.com for
directions and contact information for the local Quest Diagnostics Patient Service Centers in your area. Please call to schedule an appointment for your drug screen and bring the enclosed Custody and Control Form with you to your appointment.

  

	c)	Successful verification of your signed certification that you are not an Ineligible Person as defined in the Adolor Corporation Certification List of Parties Excluded From Federal
Programs. 

 In this position, you will receive a base salary of $27,083.33 per month, the equivalent of $325,000 on an annual basis, subject
to the normal payroll withholding taxes in accordance with the Company’s customary practices. Adolor’s current pay practice is to make direct payroll deposits on alternate Fridays. 
 Benefits 
 As a full time employee, you will be eligible to
participate in the Company’s employee benefit programs. Currently these benefits include: 
  

	•	 	 Medical, prescription, and vision benefits through Aetna, and dental insurance coverage through Aetna. As is the current practice in our industry, we ask that
employees contribute a portion of the medical and dental insurance premiums. Your medical and dental insurance will be effective on the first day of the month following your start date. 

  

	•	 	 Short Term Disability and Long Term Disability insurance, at no cost to you. These benefits are effective the first day of your employment.

  

	•	 	 A Company paid term life insurance plan equivalent to twice your annual salary up to a maximum of $400,000, at no cost to you. This benefit is effective the first
day of your employment. 

  

					
	 Confidential
	 		 	 Page 1

	•	 	 A 401(k) Retirement Savings Plan is available through The Principal Life Insurance Company to all employees on the first day of the month following enrollment and
once you meet the plan requirements. The 401(k) Plan is provided to help you prepare for your retirement through pre-tax savings. The Company will make matching contributions to your 401(k) account according to the plan provisions.

  

	•	 	 Twenty (20) days of vacation on an annual basis. You will accrue a portion of your annual vacation amount for use throughout the year. As a new hire, your
vacation accrual will be pro-rated your first year based on your start date. 

  

	•	 	 Nine (9) Company holidays and one (1) floating holiday that can be scheduled by you in calendar year 2008. You will be eligible for all Company holidays
that follow your start date. 

  

	•	 	 Access to an Employee Resource Program for you and your eligible dependents. 

 You should be aware that benefits are subject to change at the discretion of the Company. 
 Incentive Compensation

 You may also be eligible to participate in the Adolor Corporation Incentive Compensation Plan in the 2008 performance year; a copy of the Plan is
enclosed. Bonuses are discretionary, and are subject to the approval of the Board of Directors. Your annual bonus target will be 30% of your base salary based on your performance against individual objectives and the achievement of Company
milestones. You are not eligible for a bonus payment until after completion of 90 days of employment. As a new hire, your bonus payment may be pro-rated your first year based on the first day of the month following your start date. These bonus
payments are currently paid out shortly following year-end and you must be employed by the Company to receive any bonus. 
 Annual Performance Review

 Your individual performance will be evaluated during our 2008 annual review process. Currently, our annual review process takes place at the end of
each calendar year, followed by the merit increase process in January. You will receive a review during our 2008 Performance Review cycle, which may include a year-end review of your cash compensation and stock options. As a new hire, your merit
increase may be pro-rated your first year based on the first day of the month following your start date. 
 Stock Option Program 
 Upon joining the Company, you will have the opportunity to participate in the Company’s stock option program. Subject to the approval of the Compensation Committee,
you will be offered an option to purchase 125,000 shares of Adolor’s common stock. These options will be subject to the terms of Adolor Corporation’s Amended and Restated 1994 Equity Compensation Plan (“the 1994 Plan”). A copy of
the 1994 Plan is attached for your reference. The options will be Incentive Stock Options to the maximum extent available under tax regulations and your right to purchase the stock (exercise a portion of the option) will vest in equal monthly
amounts over a 48-month period commencing on your start date, subject to an initial three month waiting period. 
  

					
	 Confidential
	 		 	 Page 2

 At the time of the annual review, if your performance is satisfactory or better, you will be considered for additional
discretionary option grants which may be pro-rated your first year based on the first day of the month following your start date. 
 Adolor Stock

 Please note that under Adolor’s Policy concerning Trading in Securities and Conflicts of Interest (Policy #LGL002) employees are not permitted
to purchase or sell shares of Adolor stock without written pre-approval from the office of the General Counsel. 
 Termination of Employment 

 You will have the right to terminate your employment hereunder with or without Good Reason (as defined below), as provided below, and the Company will have
the right to terminate your employment hereunder with or without Cause or (as defined below), as provided below. Except as provided for in the immediately following paragraph, if your employment hereunder is terminated at any time (i) by you
for Good Reason following 15 days prior written notice to the Company, or (ii) by the Company without Cause, or if a Change in Control occurs and your employment hereunder is terminated at any time during the 90 days before or the first twelve
months following such Change in Control (i) by you for Good Reason following 15 days prior written notice to the Company, or (ii) by the Company without Cause, you will be entitled to receive from the Company (a) in twelve monthly
installments a payment in gross amount equal to the sum of (i) your Base Salary and (ii) the bonus amount paid to you for your performance during the immediately preceding calendar year, (b) continuation of similar benefits in effect
as of the date of termination for a period of one year following the date of termination at the Company’s sole expense, (c) immediate payment of any unpaid expense reimbursements, deferred compensation and unused accrued vacation days
through the date of termination, (d) any other payments and/or benefits which you are entitled to receive under the terms and provisions of any of the employee pension, incentive, or welfare benefit plans of the Company. 
 In the event your employment is terminated (i) by you voluntarily without Good Reason, or (ii) by the Company for Cause, you will only be entitled to receive
from the Company (a) your Base Salary through the date of such termination, (b) immediate payment of any unpaid expense reimbursements, deferred compensation and unused accrued vacation days through the date of termination, and
(c) any other payments and/or benefits which you are entitled to receive under the terms and provisions of any employee pension, incentive or welfare benefit plans of the Company. 
 If your employment is terminated due to your death, your estate will be entitled to receive from the Company (a) Base Salary continuation through the end of the month in which your death occurs, (b) a
pro-rated bonus payment for the year of death equal to the bonus amount paid to you for your performance during the immediately preceding calendar year multiplied by a fraction, the numerator of which is the number of days from and including
January 1 of such year through the date of your death and the denominator of which is 365, (c) immediate payment of any unpaid expense reimbursements, deferred compensation and unused accrued vacation days through the date of death or such
termination, and (d) any other payments and/or benefits which you are entitled to receive under the terms and provisions of any employee pension, incentive or welfare benefit plans of the Company. 
  

					
	 Confidential
	 		 	 Page 3

 In the event of any termination of your employment, you will be under no obligation to seek other employment and there
will be no offset against any amounts due to you hereunder on account of any remuneration attributable to any subsequent employment that you may obtain. Any amounts due under “Termination of Employment” are in the nature of severance
payments, or liquidated damages, or both, and are not in the nature of a penalty. Notwithstanding the foregoing, the Company’s obligation to provide continuation of benefits under the welfare benefit plans described above shall cease if you
become eligible for other health insurance benefits at the expense of a new employer. You agree to notify a duly authorized officer of the Company, in writing, immediately upon acceptance of any employment following the date of termination of your
employment, which provides you with eligibility for health insurance benefit. 
 For purposes of the Agreement, “Cause” means (a) your
conviction (including a plea of guilty or nolo contendere) of a felony under federal law or the law of the state in which such action occurred, (b) the commitment by you of an intentional act of fraud, embezzlement, or theft in connection with
your duties in the course of your employment with the Company, or your engagement in gross negligence in the course of your employment with the Company or (c) your willful and deliberate failure to perform your employment duties in any material
respect. For purposes of the Agreement, an act or omission on your part shall be deemed “intentional” or gross negligence only if it was done by you in bad faith, not merely an error in judgment, and without reasonable belief that the act
or omission was in the best interest of the Company. 
 For purposes of the Agreement, “Good Reason” means and will be deemed to exist if, without
your prior express written consent, (i) you are assigned any duties or responsibilities inconsistent in any respect with the scope of the duties or responsibilities associated with your title or position, as set forth and described above;
(ii) you suffer a material change in the duties, responsibilities, reporting rights or obligations, or effective authority associated with your title and position and/or as set forth above; (iii) your Base Salary is decreased by the
Company, or your benefits under any of the Company’s employee pension or welfare plans or programs are in aggregate materially decreased; or (iv) the Company fails to pay your compensation, employee benefits or reimbursements when due;
provided that in the event of a Change in Control, “Good Reason” shall also include the relocation of your principal office location to a site that is more than 50 miles from your then current principal office. 
 For purposes of the Agreement, “Change in Control” means (A) the consummation of a merger or consolidation of the Company in which the stockholders of the
Company immediately prior to such merger or consolidation, would not, immediately after the merger or consolidation, beneficially own (as such term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended), directly or
indirectly, shares representing the aggregate 50% or more of the combined voting power of the securities of the corporation issuing cash or securities in the merger or consolidation (or of its ultimate parent corporation, if any); or (B) the
stockholders of the Company approve a plan of complete liquidation or dissolution of the Company, or there is consummated an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets, other than a
sale or disposition by the Company of all or substantially all of the Company’s assets to an entity, at least 50% of the combined voting power of the voting securities of which are owned by persons in substantially the same proportion as their
ownership of the Company immediately prior to such sale. 
  

					
	 Confidential
	 		 	 Page 4

 If required by section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) and if Employee is a
“specified employee” of a publicly traded corporation under section 409A of the Code, payment of any amount under this Agreement shall be delayed for a period of six (6) months after separation from service, as required by section
409A of the Code. The accumulated postponed amount shall be paid in a lump sum payment within ten (10) days after the end of the six (6)-month period. If Employee dies during the postponement period prior to payment of the postponed amount, the
amounts withheld on account of section 409A of the Code shall be paid to the personal representative of Employee’s estate within sixty (60) days after the date of Employee’s death. The determination of “specified employees”
shall be made by the Compensation Committee of the Board of Directors of the Company in accordance with section 409A of the Code and the regulations issued thereunder. 
 COMPLIANCE WITH LAW. This Agreement is intended to comply with the requirements of section 409A of the Code, and shall in all respects be administered in accordance with section 409A of the Code. Notwithstanding
anything in the Agreement to the contrary, distributions may only be made under the Agreement upon an event and in a manner permitted by section 409A of the Code or an applicable exemption. All payments to be made upon a termination of employment
under this Agreement may only be made upon a “separation from service” under section 409A. For purposes of section 409A of the Code, the right to a series of payments under this Agreement shall be treated as a right to a series of separate
payments. All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of section 409A of the Code, including, where applicable, the requirement that (a) any reimbursement
shall be for expenses incurred during Employee’s lifetime (or during a shorter period of time specified in this Agreement), (b) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during a calendar year may not
affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year, (c) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which
the expense is incurred, and (d) the right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. 
 Conditions of Employment 
 As a condition of employment with the Company, which you understand to be at-will employment, we require
that you sign the enclosed Employee Noncompetition, Nondisclosure and Development Agreement and return it to me. This offer will expire at 5:00 p.m. on June 19, 2008 unless you accept it prior to that time. If you wish to accept this offer
based on the terms defined in this letter, please call me at 484-595-1975. Please sign, date, and return the enclosed copy together with the signed Employee Noncompetition, Nondisclosure and Development Agreement in the envelope enclosed.
Please do not fax either of these documents to Adolor. 
  

					
	 Confidential
	 		 	 Page 5

 Mr. Webster, we sincerely hope that you will accept our offer and we are eager to have you join Adolor Corporation.
We would anticipate, if you accept our offer that your employment would begin on or before July 1, 2008. We are looking forward to working with you and supporting you in your work so that your contributions lead the Company to even greater
future success. 
 Please feel free to call me if you have any questions about this offer or any other aspect of Adolor. 
 Sincerely, 
  

	
	 /s/ Rosemarie Eppinger

	Rosemarie Eppinger, MS, SPHR
	Sr. Director, Human Resources

 I acknowledge receipt of this offer and understand that I will be an at-will employee and that this
offer letter does not constitute an employment contract. 
  

					
	 /s/ Stephen Webster
	  		  	 June 13, 2008

	Signature	  		  	Date

 Please provide the following information for Human Resources Use ONLY 
  

			
	  

	Social Security #	  	Middle Initial
	
	  

	Anticipated Start Date	  	

  

					
	 Confidential
	 		 	 Page 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00143-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00143-of-00352.parquet"}]]